Last reviewed · How we verify

PF-06939999 in combination with docetaxel (pf-06939999-in-combination-with-docetaxel)

Pfizer · FDA-approved discontinued Quality 45/100

PF-06939999 in combination with docetaxel is an investigational therapy being developed by Pfizer Inc. for the treatment of advanced or metastatic solid tumors. The combination aims to enhance the efficacy of docetaxel by leveraging the unique mechanism of PF-06939999. Despite promising early results, the therapy has not yet received FDA approval. Clinical trials are ongoing to evaluate its safety and efficacy in various cancer types. The therapy is designed to target specific pathways involved in tumor growth and progression, potentially offering a new treatment option for patients with limited therapeutic choices.

At a glance

Generic namepf-06939999-in-combination-with-docetaxel
SponsorPfizer
Drug classSmall molecule inhibitor
TargetSpecific protein kinase
Therapeutic areaOncology
PhaseFDA-approved
First approvalNot yet determined

Approved indications

Pipeline indications

Common side effects

No common side effects on file.

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: